

## www.FirstRanker.com

## www.FirstRanker.com

FINAL EXAM JUNE 2012

# NATIONAL BOARD OF EXAMINATIONS

### CARDIOLOGY

#### PAPER-I

Time: 3 hours Max. Marks : 100 CARD/J/12/05/I

Attempt all questions in order. Each question carries 10 marks.

| 1.  | Describe coagulation pathways and indicate where the anticoagulants         | 5+5   |
|-----|---|-------|
|     | interfere.  |       |
| 2.  | Describe the anatomy of triangle of Koch's. Explain the mechanism of        | 3+4+3 |
|     | paroxysmal junctional reciprocating tachycardia. How is it treated?         |       |
| 3.  | What are hypercoagulable states? What are the laboratory tests for their    | 3+3+4 |
|     | diagnosis? Outline management of hypercoagulable state.                     |       |
| 4.  | Describe invasive and non-invasive evaluation of pulmonary arterial         | 3+3+4 |
|     | hypertension. How will you assess reversibility?                            |       |
| 5.  | What is coronary flow reserve? Describe its clinical significance.          | 5+5   |
| 6.  | Discuss genetics & manifestation of ventricular non-compaction.             | 5+5   |
| 7.  | Describe embryogenesis of conotruncal anomalies. Classify double            | 4+3+3 |
|     | outlet right ventricle and correlate with manifestations.                   |       |
| 8.  | Describe Fick principle and estimation of cardiac output by this principle. | 5+5   |
| 9.  | Discuss the principles and cardiovascular applications of Optical           | 5+5   |
|     | Coherence Tomography (OCT).   |       |
| 10. | Discuss genetics of long QT syndrome & its clinical relevance.              | 5+5   |

 $POSSESSION/USE\ OF\ CELL\ PHONES\ OR\ ANY\ SUCH\ ELECTRONIC\ GADGETS\ IS\ NOT\ PERMITTED\ INSIDE\ THE$   $EXAMINATION\ HALL$ 

## www.FirstRanker.com

FINAL EXAM JUNE 2012

#### NATIONAL BOARD OF EXAMINATIONS

## CARDIOLOGY

#### PAPER- II

Time: 3 hours Max. Marks : 100 CARD/J/12/05/II

Attempt all questions in order. Each question carries 10 marks.

| 1.  | Outline the manifestation, evaluation, diagnosis and management of      | 2+3+3+2 |
|-----|---|---------|
|     | HFNEF (Heart Failure with Normal Ejection Fraction).                    |         |
| 2.  | Describe etiopathogenesis and evaluation of left main coronary disease. | 3+3+4   |
|     | What is the current status of its management?                           |         |
| 3.  | Describe in brief the role of left atrial appendage in thromboembolism. | 4+6     |
|     | Outline current status of left atrial appendage occluder devices.       |         |
| 4.  | Describe general principles, indications and regimens for infective     | 3+3+4   |
|     | endocarditis prophylaxis.   |         |
| 5.  | What are the causes and manifestation of loss of capture in cardiac     | 2+2+3+3 |
|     | pacing? Describe its diagnosis and management.                          |         |
| 6.  | What is the etiopathogenesis, manifestation and management of ARVC      | 2+4+4   |
|     | (Arrhythmogenic Right Ventricular Cardiomyopathy)?                      |         |
| 7.  | Describe anti-thrombotic therapy for non-cardiac surgery in post        | 10      |
|     | coronary stenting.  |         |
| 8.  | What is peripartum cardiomyopathy? Discuss its risk factors; treatment  | 3+3+3+1 |
|     | and prognosis.  |         |
| 9.  | Discuss etiology and management of pacemaker implant infection.         | 5+5     |
| 10. | What is stent thrombosis? Discuss its etiopathogenesis and diagnostic   | 2+4+4   |
|     | criteria.   |         |

POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL



## www.FirstRanker.com

FINAL EXAM JUNE 2012

#### NATIONAL BOARD OF EXAMINATIONS

#### **CARDIOLOGY**

#### PAPER-III

Time: 3 hours Max. Marks : 100 CARD/J/12/05/III

Attempt all questions in order. Each question carries 10 marks.

| 1.  | Describe 'COURAGE Trial'. What is the contribution of the trial to clinical | 4+6   |
|-----|---|-------|
|     | practice?   |       |
| 2.  | Discuss the role of MRI in ischemic cardiomyopathy, hypertrophic            | 3+3+4 |
|     | cardiomyopathy & arrhythmogenic right ventricular dysplasia.                |       |
| 3.  | What are bioabsorbable stents? Outline their current status.                | 3+7   |
| 4.  | What is micro T wave alterans? What is their role in cardiac                | 3+7   |
|     | arrhythmogenesis?   |       |
| 5.  | Discuss current status of fetal cardiac intervention.                       | 10    |
| 6.  | Discuss current status of PFO (patent foramen ovale) in cardiovascular      | 6+4   |
|     | disease and PFO closure.  |       |
| 7.  | Discuss indications and current status of tissue heart valves.              | 3+7   |
| 8.  | What are drug eluting balloons? What is their present status in             | 5+5   |
|     | interventions?  |       |
| 9.  | What are leadless pacemakers? What is the current status of leadless        | 5+5   |
|     | permanent cardiac pacing devices?   |       |
| 10. | Discuss the role of renal denervation in treatment of hypertension          | 10    |

 $POSSESSION/USE\ OF\ CELL\ PHONES\ OR\ ANY\ SUCH\ ELECTRONIC\ GADGETS\ IS\ NOT\ PERMITTED\ INSIDE\ THE$   $EXAMINATION\ HALL$